I4161
IL-2 mouse
≥97% (SDS-PAGE), recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture
Sinónimos:
IL-2, Interleukin-2, T-cell growth factor, mIL-2
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Acerca de este artículo
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleServicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleNombre del producto
Interleukin-2 from mouse, IL-2, recombinant, expressed in E. coli, carrier free
biological source
mouse
recombinant
expressed in E. coli
assay
≥97% (SDS-PAGE)
form
lyophilized powder
potency
≤0.2 ng/mL ED50
quality
endotoxin tested
mol wt
17.2 kDa
packaging
pkg of 5X20 μg
pkg of 20 μg
technique(s)
cell culture | mammalian: suitable
impurities
≤0.200ng/ml
color
white
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
Quality Level
Gene Information
mouse ... Il2(16183)
¿Está buscando productos similares? Visita Guía de comparación de productos
Biochem/physiol Actions
Interleukin-2 (IL-2) is a powerful immunoregulatory lymphokine produced by T-cells in response to antigenic or mitogenic stimulation. Recombinant human IL-2 is a 15.5 kDa protein, containing 134 amino acid residues including one intrachain disulfide bond.
Physical form
Lyophilized with no additives.
Preparation Note
Centrifuge vial prior to opening. Reconstitute the contents of the vial in water to a concentration range of 0.1-1.0 mg/mL.
IL-2 is a powerful immunoregulatory lymphokine produced by T-cells in response to antigenic or mitogenic stimulation. IL-2/IL-2R signaling is required for T-cell proliferation and other fundamental functions which are essential for the immune response. IL-2 stimulates growth and differentiation of B-cells, NK cells, lymphokine activated killer cells, monocytes, macrophages and oligodendrocytes. Recombinant human IL-2 is a 15.5 kDa protein, containing 134 amino acid residues including one intrachain disulfide bond.
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - STOT SE 3
target_organs
Respiratory system
Clase de almacenamiento
10 - Combustible liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Joaquin De Haro et al.
Journal of vascular surgery, 62(6), 1625-1631 (2014-07-22)
This study assessed the effect of cellular and humoral autoimmune response inhibition after immunization with β2-glycoprotein I (β2-GPI) and the effect of immunomodulation with interleukin (IL)-2 and IL-10 in the development of early atherosclerotic vascular lesion in a murine model.
Nabil Ahmed et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33(15), 1688-1696 (2015-03-25)
The outcome for patients with metastatic or recurrent sarcoma remains poor. Adoptive therapy with tumor-directed T cells is an attractive therapeutic option but has never been evaluated in sarcoma. We conducted a phase I/II clinical study in which patients with
Fang-Ting Lu et al.
Journal of autoimmunity, 61, 62-72 (2015-06-15)
Thymic CD4(+) FoxP3(+) regulatory T (Treg) cells are critical for the development of immunological tolerance and immune homeostasis and requires contributions of both thymic dendritic and epithelial cells. Although B cells have been reported to be present within the thymus
Larisa Kizima et al.
PloS one, 9(4), e94547-e94547 (2014-04-18)
Prevalent infection with human herpes simplex 2 (HSV-2) or human papillomavirus (HPV) is associated with increased human immunodeficiency virus (HIV) acquisition. Microbicides that target HIV as well as these sexually transmitted infections (STIs) may more effectively limit HIV incidence. Previously
Sushama Telwatte et al.
Nucleic acids research, 43(6), 3256-3271 (2015-03-15)
Resistance to combined antiretroviral therapy (cART) in HIV-1-infected individuals is typically due to nonsynonymous mutations that change the protein sequence; however, the selection of synonymous or 'silent' mutations in the HIV-1 genome with cART has been reported. These silent K65K
Contenido relacionado
Instructions
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico